Latest filingAug 26, 2026Most recent Form 4
CVM
CEL SCI CORP
NYSEHealthcareBiological Products, (No Diagnostic Substances)
Insider activity for last month from 08/03 to 09/03. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$13.8M1 buys
Total selling$00 sells
Net open-market+$13.8M6 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period7transactions
- A · Grants / awards · dominant6 · 86%
- P · Open-market buys1 · 14%
Activity by reported role
A joint filing can contribute to multiple roles7transactions
- Chief executive officer · dominant2 · 29%
- Director2 · 29%
- Chief financial officer1 · 14%
- CSO1 · 14%
- SVP1 · 14%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (6)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeKersten Geert ROptions · Direct
452,380Aug 14, 2026
Prichep Patricia BOptions · Direct
299,693Aug 14, 2026
Talor EyalOptions · Direct
331,625Aug 14, 2026
Cipriano JohnOptions · Direct
118,010Aug 14, 2026
Baillavoine Bruno Jean-MarieOptions · Direct
138,021Aug 14, 2026
Watson Robert EugeneOptions · Direct
137,271Aug 14, 2026
Kersten Geert RCommon Stock · Direct
316,142Aug 25, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 03 → Sep 03
LessMore
Top insiders
By absolute net value across the selected period- KR+$3.0k
- TE+$2.5k
- PB+$2.3k
- WE+$1.1k
- BJ+$1.1k
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
CVM transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| CVM | Watson Robert Eugene | DIR | grant | 110k | $110k | A | +3.9% | 08/17 | 08/14 | |
| CVM | BAILLAVOINE BRUNO JEAN-MARIE | DIR | grant | 110k | $110k | A | +3.9% | 08/17 | 08/14 | |
| CVM | CIPRIANO JOHN | SVP | grant | 80.0k | $80.0k | A | +3.9% | 08/17 | 08/14 | |
| CVM | TALOR EYAL | CSO | grant | 250k | $250k | A | +3.9% | 08/17 | 08/14 | |
| CVM | PRICHEP PATRICIA B | CFO | grant | 225k | $225k | A | +3.9% | 08/17 | 08/14 | |
| CVM | KERSTEN GEERT R | CEO | grant | 300k | $300k | A | +3.9% | 08/17 | 08/14 |
CEL SCI CORP Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at CEL SCI CORP?
KERSTEN GEERT R, Watson Robert Eugene, BAILLAVOINE BRUNO JEAN-MARIE, CIPRIANO JOHN, TALOR EYAL, PRICHEP PATRICIA B.
When was the latest reported open-market purchase?
Kersten Geert R reported a buy on Aug 25, 2026 valued at $13.8M. Read the SEC filing.
When was the latest reported open-market sale?
No code-S sale is available for this period.
What is the recent purchase and sale balance?
Net open-market buying in the selected period was $138,000.00. This describes filed transactions, not a bullish rating.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.